Here are four things to know:
1. The trial will run alongside the two ongoing pivotal U.S. Phase III trials in colonoscopy and bronchoscopy.
2. The trial is part of the development program that PAION and the FDA agreed upon for the filing of Remimazolam in the targeted indication ‘procedural sedation’.
3. Remimazolam is an ultra-short-acting intravenous sedative and anesthetic.
4. This double-blind, randomized, multicenter, parallel group study includes around 75 high-risk patients undergoing a colonoscopy.
More articles on GI/endoscopy:
ASGE launches clinical practice guideline app: 3 things to know
Dr. Noel Fajardo to open LV Surgery Center in Nevada: 3 things to know
Giving thanks in GI: 5 gastroenterologists on what they are most grateful for
